ClinicalTrials.gg
WithdrawnNCT06522477Updated Oct 18, 2024

High Vs Low Intensity Virtual Reality Gait Training in Individuals with Chronic Stroke

An interventional study of Virtual reality gait training in Stroke and Gait Disorders, Neurologic, sponsored by Indiana University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Did not receive funding
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this pilot study is to investigate the feasibility of 1) providing virtual reality walking training using a custom developed setup able to be replicated in routine clinical practice and 2) combining the virtual reality training with high-intensity gait training.

Read the detailed description

This study will utilize a randomized-crossover design. Following confirmation of eligibility and completion of Baseline 1 testing, individuals will be randomized to receive up to 15 visits over approximately 5 weeks of either high or low intensity virtual reality gait training. Following which, individuals will undergo Post 1 testing to capture potential change in outcomes following the intervention. Participants will then take at least a 4-week break before returning to complete Baseline 2 testing and up 15 visits over 5 weeks of the alternative intervention before finally completing Post 2 testing.

02

Conditions studied

  • Stroke
  • Gait Disorders, Neurologic

Keywords

  • stroke
  • gait
  • rehabilitation
  • high-intensity
  • virtual reality
03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

Browse Stroke studies →

Lead sponsor

Indiana University is the lead sponsor of 982 studies on the registry; 199 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 117 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral deficits following stroke > 6 months prior; however individuals > 4 months post-stroke are eligible for consenting, but final eligibility and potential enrollment will not occur until > 6 months
  • Age 18-85 years
  • Weight \< 350 pounds
  • Able to follow a 3-step command
  • Able to ambulate with self-selected gait speeds between 0.01-1.0 m/s without physical assistance, but with below knee bracing and/or assistive device as needed
  • Lower extremity Fugl-Meyer \< 34
  • Medical clearance to participate

Exclusion criteria

Exclusion Criteria:

  • Evidence of cerebellar ataxia
  • Uncontrolled cardiopulmonary or metabolic disease that limits exercise participation, active heterotopic ossification, recurrent history of lower extremity fractures, previous orthopedic or other peripheral or central neurologic injury that may impair locomotor activities
  • Currently participating in other physical therapy
  • > 50 units of Botox in the lower extremity OR in the lower extremity, but above the knee if the participant wears an ankle-foot-orthosis (AFO) within the past three months. Note that participants may be consented prior to 3 months post-injection; however, eligibility will be determined post 3 months.
  • Unable to read > 50% of the letters on the 20/70 line of the Snellen Chart with customary eye wear at a distance of 20 feet
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    High-intensity followed by low-intensity virtual reality gait training

    Individuals randomized to this group will first perform high-intensity virtual reality gait training and following a 4-week washout period will complete low-intensity virtual reality gait training.

    Other: Virtual reality gait training

  • Experimental
    Low-intensity followed by high-intensity virtual reality gait training

    Individuals randomized to this group will first perform low-intensity virtual reality gait training and following a 4-week washout period will complete high-intensity virtual reality gait training.

    Other: Virtual reality gait training

Interventions

  • OtherVirtual reality gait training

    Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.

06

What researchers measure

Primary outcomes

  1. Gait speed

    This is an assessment of overground walking speed measured across a distance of \~20 feet and will be conducted at both self-selected (instructions: "walk at your usual, comfortable pace") and fastest (instructions: "walk as fast as you safely can") walking speeds.

    Time frame: After 5 weeks of training

  2. 6 minute walk test

    Individuals will be asked to "cover as much ground as possible" over a six minute period.

    Time frame: After 5 weeks of training

  3. Peak treadmill speed

    Individuals will participate in a walking-based graded exercise test. While harnessed for safety on a treadmill, the treadmill will be initially set to 0.1 m/s and increased by 0.1 m/s each minute until the test is terminated due to one of the following: 1) the participant requests to stop, 2) the participant is unable to keep up with the speed of the treadmill and/or loses their balance, 3) any of the absolute exercise test termination criteria provided by American College of Sports Medicine are present. The highest speed that the individual can walk for a minute at is the peak treadmill speed.

    Time frame: After 5 weeks of training

Secondary outcomes

  1. Mini Balance Evaluation Systems Test

    14 item assessment of static and dynamic balance. Example tasks include sit to stand, stand on one leg, standing stepping reactions, and walking with head turns.

    Time frame: After 5 weeks of training

  2. Steps per Day

    Participants will wear a research-grade pedometer (StepWatch; Modus Health) during waking hours for \~1-2 weeks before beginning each training protocol and after completing training protocol to quantify home and community mobility.

    Time frame: After 5 weeks of training

  3. 30 second Sit to Stand Test

    Participants will be asked to rise from a chair without using their arms and then return to sitting as many times as possible in 30 seconds.

    Time frame: After 5 weeks of training

  4. Activity-Specific Balance Confidence (ABC) Scale

    This questionnaire asks individuals to rate their balance-confidence from 0 (no confidence) to 100 (completely confident) during a variety of 16 commonly performed tasks such as walking around a house or getting into a car.

    Time frame: After 5 weeks of training

  5. Medical Outcomes Survey Short-Form 36 (SF-36)

    This 36-question survey asks individuals about how their current health may limit their ability to perform typical physical and social activities. Scores range from 0 (negative health) to 100 (positive health).

    Time frame: After 5 weeks of training

  6. Oxygen Consumption

    Oxygen consumption will be measured via a portable metabolic cart (K5; COSMED) during the previously described graded exercise test. Participant will wear a snug fitting mask that covers their mouth and nose, but does not affect the amount or quality of air that they breathe. The mask will be connected to a small backpack that collects information on the rate of breathing and oxygen consumed.

    Time frame: After 5 weeks of training

07

Study locations

1 site
  • Rehabilitation Hospital of Indiana
    Indianapolis, Indiana 46254, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data available upon reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: after completion of study for 3 years

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06522477
Lead sponsor
Indiana University
Responsible party
Christopher Henderson (Assistant Research Professor, Indiana University) — Principal investigator
First posted
Jul 26, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Oct 18, 2024

Study contacts

Christopher Henderson, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion